Actively Recruiting

Phase Not Applicable
Age: 22Years - 70Years
All Genders
NCT04184973

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Led by Colospan Ltd. · Updated on 2025-10-23

250

Participants Needed

14

Research Sites

340 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

A randomized trial to assess the safety and efficacy of CG-100 for reducing stoma creation rate in subjects undergoing mesorectal excision.

CONDITIONS

Official Title

Efficacy and Safety of the CG-100 Intraluminal Bypass Device

Who Can Participate

Age: 22Years - 70Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Willingness to comply with follow-up evaluations as per the study protocol
  • Aged 22 to 65 years, or 66 to 70 years with up to one treated cardiovascular, metabolic, or pulmonary condition
  • Diagnosed with colorectal cancer
  • Scheduled for elective open, laparoscopic, or robotic mesorectal excision with an anastomosis up to 10 cm from the anal verge
  • Scheduled to receive a protective stoma during the primary planned surgery
  • Planned mechanical bowel preparation before surgery
  • Provided informed consent approved by an ethics committee or institutional review board
Not Eligible

You will not qualify if you...

  • Presence of local or systemic infection at the time of intervention, such as peritonitis
  • Major surgical or interventional procedures within 45 days before the study or planned within 6 months after entry (except port placement for chemotherapy or ureter stent insertion)
  • ASA classification greater than 3
  • Albumin level below 30 g/liter
  • Diagnosis of bowel obstruction, strangulation, peritonitis, perforation, ischemic bowel, carcinomatosis, or widespread inflammatory bowel disease
  • Diagnosis of coagulopathy, thrombocytopenia, or immune suppression
  • Body mass index of 40 or higher
  • Undergoing additional surgical procedures during surgery other than ileostomy or adhesiolysis
  • Current participation in another investigational drug or device study unless approved by the sponsor
  • Regular systemic or steroid medication use in the last 6 months
  • Use of antimetabolites or antiplatelet agents
  • Preexisting sphincter problems
  • Extensive local disease in the pelvis or prior pelvic anastomosis
  • Massive diverticulosis in the sigmoid or descending colon seen on preoperative CT
  • Any condition that could jeopardize safe participation or data quality as judged by the investigator
  • Pregnant or nursing females; females of childbearing potential must have a negative pregnancy test within 7 days before surgery

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 14 locations

1

University of California Irvine

Orange, California, United States, 92868

Actively Recruiting

2

Kaiser Permanente San Diego medical Center

San Diego, California, United States, 92123

Actively Recruiting

3

Colorado University Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

4

University of Louisville

Louisville, Kentucky, United States, 40202

Active, Not Recruiting

5

Henry Ford Health System

Detroit, Michigan, United States, 48202

Active, Not Recruiting

6

East Bank Hospital - M Health Fairview University of Minnesota Medical Center

Minneapolis, Minnesota, United States, 55455

Active, Not Recruiting

7

New York-Presbyterian / Weill Cornell Medical Center

New York, New York, United States, 10021

Active, Not Recruiting

8

Jefferson University Hospital

Philadelphia, Pennsylvania, United States, 19107

Active, Not Recruiting

9

Lifespan & Brown Surgical Associates

Providence, Rhode Island, United States, 02906

Active, Not Recruiting

10

University of Utah Health

Salt Lake City, Utah, United States, 84132

Active, Not Recruiting

11

Soroka University Medical Center

Beersheba, Israel, 85025

Actively Recruiting

12

Carmel Medical Center

Haifa, Israel, 8250490

Actively Recruiting

13

Rabin Medical Center

Petah Tikva, Israel, 49100

Withdrawn

14

Humanitas Research Hospital

Milan, Lombardy, Italy, 20089

Actively Recruiting

Loading map...

Research Team

J

Jonathan Elsner, PhD, MBA

CONTACT

S

Shelly Sharon, MSc

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here